Despite faster reviews, many global drugs never reach Japan. Learn how early development decisions, trial design, and access policies shape today’s drug lag.
Novartis used PBPK modeling for therapeutic regulatory success. They used model simulations to replace clinical studies, predict DDIs, and support asciminib’s approval.
